Jefferies Group LLC assumed coverage on shares of Axovant Sciences Ltd. (NYSE:AXON) in a report released on Monday, July 10th, Marketbeat Ratings reports. The brokerage issued a buy rating and a $40.00 price objective on the biotechnology company’s stock.
Other analysts also recently issued reports about the stock. Cowen and Company reiterated an outperform rating and issued a $30.00 price objective on shares of Axovant Sciences in a report on Wednesday, June 21st. BidaskClub downgraded shares of Axovant Sciences from a buy rating to a hold rating in a report on Thursday, July 6th. Piper Jaffray Companies reiterated an overweight rating and issued a $32.00 price objective on shares of Axovant Sciences in a report on Wednesday, April 12th. Oppenheimer Holdings, Inc. lifted their price objective on shares of Axovant Sciences from $30.00 to $33.00 and gave the company a neutral rating in a report on Monday, April 17th. Finally, CIBC boosted their target price on shares of Axovant Sciences from $30.00 to $33.00 and gave the stock a neutral rating in a report on Tuesday, April 18th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $28.50.
Axovant Sciences (NYSE:AXON) traded up 1.39% during trading on Monday, reaching $23.40. 342,231 shares of the company’s stock traded hands. Axovant Sciences has a 1-year low of $11.01 and a 1-year high of $26.49. The stock’s market capitalization is $2.51 billion. The stock has a 50-day moving average price of $22.85 and a 200 day moving average price of $18.65.
Axovant Sciences (NYSE:AXON) last released its quarterly earnings data on Tuesday, June 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.02. Equities research analysts expect that Axovant Sciences will post ($2.20) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This article was first published by BBNS and is owned by of BBNS. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://baseballnewssource.com/markets/jefferies-group-llc-initiates-coverage-on-axovant-sciences-ltd-axon-updated-updated-updated/1179958.html.
Large investors have recently made changes to their positions in the stock. Oppenheimer & Co. Inc. acquired a new stake in shares of Axovant Sciences during the first quarter worth about $219,000. Primecap Management Co. CA increased its position in shares of Axovant Sciences by 300.1% in the first quarter. Primecap Management Co. CA now owns 2,878,930 shares of the biotechnology company’s stock valued at $43,011,000 after buying an additional 2,159,428 shares during the last quarter. American International Group Inc. increased its position in Axovant Sciences by 7.1% in the first quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock valued at $225,000 after buying an additional 998 shares in the last quarter. JPMorgan Chase & Co. increased its position in Axovant Sciences by 4.1% in the first quarter. JPMorgan Chase & Co. now owns 489,024 shares of the biotechnology company’s stock valued at $7,306,000 after buying an additional 19,129 shares in the last quarter. Finally, C WorldWide Group Holding A S purchased a new position in Axovant Sciences during the first quarter valued at about $1,637,000. 94.44% of the stock is owned by institutional investors.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with our FREE daily email newsletter.